Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers

Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers

Background Clinical studies have highlighted the efficacy of anti-programmed death 1 (αPD-1) monoclonal antibodies in patients with DNA mismatch repair-deficient (MMRD) tumors. However, the responsiveness of MMRD cancers to αPD-1 therapy is highly heterogeneous, and the origins of this variability r...

Full description

Bibliographic Details
Main Authors: Jean-Yves Scoazec, Antoine Hollebecque, Aurélien Marabelle, Alexandra Leary, Lydie Cassard, Nathalie Chaput, Cristina Smolenschi, Perrine Vuagnat, Jean-Mehdi Jouniaux, Laetitia Nebot-Bral, Andrey A Yurchenko, Louise de Forceville, Mathieu Danjou, Reginaldo C A Rosa, Caroline Pouvelle, Said Aoufouchi, Emeline Colomba, Sergey Nikolaev, Patricia Kannouche
Format: Article
Language:English
Published: BMJ Publishing Group 2022-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/10/7/e005059.full

Internet

https://jitc.bmj.com/content/10/7/e005059.full

Similar Items